Autologous tumor idiotype (Id)

Autologous tumor idiotype refers to the unique set of antigenic determinants found in the variable regions of the immunoglobulin (Ig) molecules expressed on the surface of malignant B-cells (Kwak LW, et al., 1992, NEJM). Because each B-cell clone produces a unique antibody, the idiotype serves as a truly tumor-specific antigen that is absent from normal B-cells and other healthy tissues (National Cancer Institute, NCI Dictionary). In therapeutic applications, this idiotype is harvested from a patient's own tumor, purified, and typically conjugated to a carrier protein like Keyhole Limpet Hemocyanin (KLH) to create a personalized vaccine (Bendig MM, et al., 2004, Methods Mol Med). The primary goal of this therapy is to stimulate the patient's immune system to recognize and eliminate the specific cancerous clone through both antibody-mediated and T-cell-mediated mechanisms (Neelapu SS, et al., 2007, Expert Opin Biol Ther). While clinical trials, such as those for Dasiprotimut-T, have demonstrated the potential to prolong disease-free survival in follicular lymphoma, the approach remains logistically intensive due to the requirement for custom manufacturing for every individual patient (Schuster SJ, et al., 2011, JCO).

Other names

Tumor-specific idiotypeB-cell idiotypeImmunoglobulin idiotypePatient-specific idiotypeId protein

Active immunotherapy involving the administration of patient-specific tumor antigens to induce a personalized humoral and cellular immune response against malignant B-cells.